Edwards announces one-year results from CLASP IID trial

Edwards Lifesciences announced one-year results from CLASP IID, the first randomized controlled trial that directly compares two contemporary mitral transcatheter edge-to-edge repair, or TEER, therapies, as well as one-year results from the CLASP IID registry. The studies confirm the clinical and quality-of-life benefits of mitral regurgitation reduction with the PASCAL system in a broad population of patients with degenerative mitral regurgitation, or DMR, the company said. Results from the CLASP IID randomized trial and registry were presented as a late-breaking clinical trial session at the 35th Transcatheter Cardiovascular Therapeutics, or TCT, the annual scientific symposium of the Cardiovascular Research Foundation, and simultaneously published in “JACC: Cardiovascular Interventions.”